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Dr John A. Elefteriades (New Haven, Conn). I congratulate the
authors on an excellent experimental investigation. This is an im-
portant topic because patients with complex cardiac surgical dis-
ease currently have excess bleeding since the withdrawal of
aprotinin. The members of our group are strong proponents of apro-
tinin. In 2006 in this Journal we published a study of patients with
aneurysms operated on with and without aprotinin. Everything was
better with aprotinin, not only blood product transfusion but also
respiratory function and other parameters.
I have a few simple questions for you. The first one has to do
with your measurement of blood loss. Why did you use sponges
rather than chest tube drainage? Also, were the operators blinded
as to study drug or no study drug?
Dr Szabo. First of all, the operator was blinded to control and the
de novo compound but not aprotinin, because aprotinin is a different
dosing scheme. The control group received continuous infusion as
placebo.
Regarding the measurement of blood loss, in our experience,
gauze bandages were more exact than using a chest tube drain.
We measured blood loss volume in the first 2 hours at the openrdiovascular Surgery c Volume 139, Number 3 739
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Schest situation. With drying the operative area with the gauze ban-
dages, we could remove all blood from the operative area.
Dr Elefteriades. Since you were doing this experiment, why
didn’t you allow the animals to survive and look for renal function
or evidence of thrombosis?
Dr Szabo. These experiments sought to establish a dose–
response relationship and to explore whether the compound has
some cardioprotective effects. As such it was designed as an acute
experiment without keeping the animals alive. However, safety is-
sues are very important, before moving to the clinical arena. These
experiments are required from the authorities in Germany and they
are running now.740 The Journal of Thoracic and Cardiovascular SurgDr Elefteriades. Some of your cardiac functional parameters
exceeded the preoperative baseline. Do you mean to imply that
your drug has a positive inotropic effect?
Dr Szabo. Actually, it was within the physiologic ranges of
a few percent, and I think it is just the physiologic variation. How-
ever, we also did pharmacokinetic experiments as dose finding pre-
vious to these experiments and in that case we measured
hemodynamics, even at the larger range of doses. We did not see
any direct inotropic effect of this drug.
Dr Elefteriades. Congratulations and I hope your drug is borne
out in further studies.
Dr Szabo. We hope so as well. Thank you very much.ery c March 2010
